Wednesday, July 8, 2026

Patent intelligence · US

US 11884715

Activin receptor type IIB variants and methods of use thereof

granted A61KA61K38/00A61K38/1709A61K38/179
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 18
Applicant portfolio 12
Patent details — US 11884715
Jurisdiction
US
Status
granted
Grant date
Jan 30, 2024
Expiration
Jan 25, 2044
Claims
14
CPC classes
A61K, A61K38/00, A61K38/1709, A61K38/179
View on Google Patents ↗

Quick answer

US 11884715 (Activin receptor type IIB variants and methods of use thereof) is held by Keros Therapeutics, Inc.. Status: granted. Granted Jan 30, 2024. Expires Jan 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
14
CPC classes
A61K, A61K38/00, A61K38/1709, A61K38/179, A61P, A61P19/00

More from Keros Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12404313

    GDNF fusion polypeptides and methods of use thereof

    Keros Therapeutics, Inc. · Expires Aug 28, 2045

    granted
  2. US 12364737

    Activin receptor type IIA variants and methods of use thereof

    Keros Therapeutics, Inc. · Expires Jul 17, 2045

    granted
  3. US 12350313

    Activin receptor type IIa variants and methods of use thereof

    Keros Therapeutics, Inc. · Expires Jul 3, 2045

    granted
  4. US 12331124

    ALK2 antibodies and methods of use thereof

    Keros Therapeutics, Inc. · Expires Jun 12, 2045

    granted
  5. US 12269858

    Activin receptor type IIB variants and methods of use thereof

    Keros Therapeutics, Inc. · Expires Apr 3, 2045

    granted
  6. US 12071438

    Crystal forms of an ALK2 inhibitor

    Keros Therapeutics, Inc. · Expires Aug 22, 2044

    granted
  7. US 11912750

    GDNF fusion polypeptides and methods of use thereof

    Keros Therapeutics, Inc. · Expires Feb 22, 2044

    granted

Frequently asked questions

What is US patent 11884715?

US 11884715 (Activin receptor type IIB variants and methods of use thereof) is held by Keros Therapeutics, Inc.. Status: granted. Granted Jan 30, 2024. Expires Jan 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11884715?

Keros Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.

When does US 11884715 expire?

Our index shows an expiration date of Jan 25, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.